The development of immunoassays for Chagas disease diagnosis is complex, considering the antigenic similarity between Trypanosoma cruzi and other trypanosomatids, such as Leishmania sp, which leads to cross-reactivity. Although T. cruzi and Leishmania sp. co-occur in many regions of Brazil, the use of chimeric recombinant T. cruzi antigens confers specificity to immunoassays and reduces cross-reactivity rates. In recent years, our group has expressed and purified four chimeric T. cruzi antigens (IBMP-8.1, -8.2, -8.3, and -8.4) and evaluated their diagnostic performance in the serological diagnosis of CD. We observed high performance and negligible cross-reactivity rates against leishmaniasis, demonstrating their usefulness in regions where T. cruzi and Leishmania spp. are coendemic. However, the impact of other zoonotic trypanosomatid infections on the performance of chimeric recombinant-based assays is unknown. Recently, non-Leishmania, Crithidia-related parasites have been associated with atypical manifestations similar to visceral leishmaniasis in patients in the Brazilian state of Sergipe. Symptoms persisted even after treatment for leishmaniasis. Therefore, the present study aims to evaluate the use of IBMP antigens for the diagnosis of chronic CD in patients with leishmaniasis-like disease, using a reference array of chimeric antigens as a gold standard. A total of ten patients with leishmaniasis-like disease were included in the study. DNA from Leishmania infantum was detected in two samples, and DNA from non-Leishmania, Crithidia-related was detected in the remaining eight samples. Human sera were used to evaluate the performance of each IBMP chimeric antigen using Latent Class Analysis (LCA) as a reference test. LCA classified eight (80%) samples as T. cruzi-negative and two (20%) as T. cruzi-positive. T. cruzi-positive samples were also positive for non-Leishmania, Crithidia-related trypanosomatids. All L. infantum samples were T. cruzi-negative. Following the serological definition of the samples as T. cruzi-positive or T. cruzi-negative by LCA, the performance parameters of IBMP chimeric proteins were determined. We observed a sensitivity of 100% for all four IBMP antigens, whereas specificity ranged from 87.5% for IBMP-8.1 and IBMP-8.3 to 100% for IBMP-8.1 and IBMP-8.4. Accuracy values ranged from 90% for IBMP-8.2 and IBMP-8.3 to 100% for IBMP-8.3 and IBMP-8.4. Despite the limited number of analyzed samples, IBMP chimeric antigens showed high diagnostic performance. In light of the low (IBMP-8.2 and IBMP-8.3) or lack of cross-reactivity (IBMP-8.1 and IBMP-8.4) with both visceral leishmaniasis and non-Leishmania, Crithidia-related trypanosomatids, we suggest the use of IBMP antigens in regions where T. cruzi and other trypanosomatids are coendemic. However, a more in-depth assessment of the cross-reactivity of IBMP antigens using a larger number of sera from non- Leishmania, Crithidia-related trypanosomatids infections is warranted.